STUDY PROTOCOL |


CUUR - study protocol

Randomized, cross-over, placebo-controlled human study pilot, which compared a CUUR® Daytime Recovery formulation to a Placebo formulation. A total of 14 participants took place in this pilot study.

The study defined 2 leading end-points:

  • Improvement / worsening of headache symptoms next morning, comparing to 60 minutes post CUUR® or Placebo consumption.
  • Improvement / worsening of nausea symptoms next morning, comparing to 60 minutes post CUUR® or Placebo consumption.

Each participant consumed a pre-calculated quantity of alcohol per his/her gender and weight along 90 minutes. Then, 15 minutes after completing alcohol consumption, each participant consumed either the CUUR® formulation or the Placebo formulation. Two measurement points of headache and nausea severity were recorded 60 minutes post CUUR® / Placebo consumption, serving as baseline; and; the severity of headache and nausea symptoms next morning, when the participants woke up.



RESULTS | The results revealed meaningful improvement in headache relief and Nausea relief

CUUR - Human study graph

The headache symptoms in the Placebo group worsened by 102% comparing with 60 minutes after Placebo consumption the same night . In contrast, the headache symptoms in the CUUR® group the next morning improved by 21%.

The nausea symptoms in the Placebo group worsened by 25% comparing with 60 minutes after Placebo consumption the same night (p = 0.0003). In contrast, the nausea symptoms in the CUUR® group the next morning improved by 67% (p = 0.0137).